Precise Detection of ProGRP Using Label-Free Electrochemical Biosensor based on α-Fe2O3/Fe3O4 heterogeneous nanorods DOI
Zhihao Xu, Hezhong Ouyang,

Haoda Zhang

et al.

Ceramics International, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 1, 2024

Language: Английский

Targeted and cytotoxic inhibitors used in the treatment of lung cancers DOI Creative Commons
Robert Roskoski

Pharmacological Research, Journal Year: 2024, Volume and Issue: unknown, P. 107465 - 107465

Published: Oct. 1, 2024

Language: Английский

Citations

4
A Recurrent Small Cell Lung Carcinoma Harboring an EML4–ALK Fusion Mutation with Sustained Response to Ensartinib: A Case Report DOI Creative Commons
Hao Jiang,

Tengfei Zhu,

Zenghao Chang

et al.

Current Oncology, Journal Year: 2025, Volume and Issue: 32(3), P. 163 - 163

Published: March 13, 2025

Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor. Lung patients with ALK and EML4 fusions respond significantly to inhibitors. The EML4-ALK fusion gene mutation the result of inversion chromosome 2, which juxtaposes 5 end 3 gene. In SCLC, frequency genes very low, best our knowledge, only four cases mutations in SCLC have been reported. this report, we describe treatment a 74-year-old female patient who developed recurrence hilar lymph node metastasis three years after surgical resection. Postoperative NGS showed that harboring rare mutation, satisfactory 43-month overall survival (OS) was achieved ensartinib targeting mutation. ALK-TKI may be new option for these patients. This article provides therapeutic reference.

Language: Английский

Citations

0
Advances in adoptive cell therapies in small cell lung cancer DOI Creative Commons

Eljie Isaak Bragasin,

Justin Cheng, Lauren Ford

et al.

Exploration of Targeted Anti-tumor Therapy, Journal Year: 2025, Volume and Issue: 6

Published: March 26, 2025

Small cell lung cancer (SCLC) is an aggressive tumor characterized by early metastasis and resistance to treatment, making it a prime target for therapeutic investigation. The current standard of care frontline treatment involves combination chemotherapeutic agents immune checkpoint inhibitors (ICIs), though durability response remains limited. genetic heterogeneity SCLC also complicates the development new options. Adoptive therapies show promise targeting specific mutations in order increase efficacy minimize toxicity. There has been significant investigation three classes application towards SCLC: antibody drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), chimeric antigen receptor (CAR)-T therapies. This review summarizes recent advances challenges adoptive Genetic targets such as delta-like ligand 3 (DLL3), trophoblast surface 2 (Trop2), B7-H3 (CD276), gangliosides disialoganglioside GD2 (GD2) ganglioside GM2 (GM2) have found be expressed SCLC, which makes them therapy development. While investigated rovalpituzumab tesirine (Rova-T) failed, several insights from these trials led compelling sacituzumab govitecan (SG), ifinatamab deruxtecan (I-DXd), tarlatamab, DLL3-targeted CAR-T cells. Advancing molecular testing improving targeted approaches remain integral pushing forward progress SCLC.

Language: Английский

Citations

0
Precise Detection of ProGRP Using Label-Free Electrochemical Biosensor based on α-Fe2O3/Fe3O4 heterogeneous nanorods DOI
Zhihao Xu, Hezhong Ouyang,

Haoda Zhang

et al.

Ceramics International, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 1, 2024

Language: Английский

Citations

3